

PRELIMINARY PROGRAM

7th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 24-27, 2017

Chairmen: **F. Lo Coco, M.A. Sanz**
Honorary President: **F. Mandelli**



7th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 24-27, 2017

Dear Colleague,

we kindly remind you that the 7th International Symposium on Actue Promyelocytic Leukemia will be held in Rome on September 24-27, 2017 (www.apl2017.com).

As you can see from the website, this conference has long since become a traditional, well established meeting that gathers togheter renowned scientist, researchers and clinicals from all over the globe. In fact, basic science, translational and clinical experts will update the audience on most recent advances related to both laboratory and clinical research in APL and related fields (differentiation treatments, targeted therapy, oncogenic signaling, minimal residual disease etc.).

In addition to clinical and research update on unpublished work, there will be an educational session to address the issues related to diagnostics and management of the disease. Furthermore, this symposium will host a forum on international collaboration and projects for implementing clinical networking on APL and available treatment resources in developing countries.

Finally, the symposium offers a great opportunity for young investigators interested in the field to present their work in dedicated oral and poster session.

Please remember that the deadline for abstract submission is June 16, 2017.

We look forward to welcoming you to the Eternal City!

Francesco Lo Coco
Symposium co-chairmen

Miguel A. Sanz
Symposium co-chairmen

FACULTY

Oussama	Abla	Toronto, Canada	Timothy	Ley	St. Louis, USA
Lionel	Adès	Paris, France	Junmin	Li	Shanghai, China
Myriam	Alcalay	Milan, Italy	Francesco	Lo Coco	Rome, Italy
Sergio	Amadori	Rome, Italy	Franco	Locatelli	Rome, Italy
William	Arcese	Rome, Italy	Bob	Lowenberg	Rotterdam, The Netherlands
Giuseppe	Avvisati	Rome, Italy	David	Martinez-Cuadron	Valencia, Spain
Nancy	Berliner	Boston, USA	Vikram	Mathews	Vellore, India
Massimo	Breccia	Rome, Italy	Wilson H.	Miller	Montreal, Canada
Mammen	Chandy	Vellore, India	Saverio	Minucci	Milan, Italy
Zhu	Chen	Shanghai, China	Pau	Montesinos	Valencia, Spain
Laura	Cicconi	Rome, Italy	Clara	Nervi	Rome, Italy
Hughes	de Thé	Paris, France	Fabrizio	Pane	Naples, Italy
Laurent	Degos	Paris, France	Pier Giuseppe	Pelicci	Milan, Italy
Fabio	Efficace	Rome, Italy	Uwe	Plazbecker	Dresden, Germany
Elihu	Estey	Houston, USA	Eduardo	Rego	Sao Paulo, Brazil
Anna	Falanga	Bergamo, Italy	Nigel	Russell	Nottingham, United Kingdom
Brunangelo	Falini	Perugia, Italy	Minguel A.	Sanz	Valencia, Spain
Pierre	Fenaux	Paris, France	Jaime	Sanz Caballer	Valencia, Spain
Felicetto	Ferrara	Naples, Italy	Matthew	Seftel	Winnipeg, Canada
Francesco	Grignani	Perugia, Italy	Jorge	Sierra	Barcelona, Spain
Syed Khizer	Hasan	Mumbai, India	Akihiro	Takeshita	Nagoya, Japan
Harry	Iland	Camperdown, Australia	Martin S.	Tallman	New York, USA
Anand	Jillella	Atlanta, USA	Anna M.	Testi	Rome, Italy
Richard	Larson	Chicago, USA	Christian	Thiede	Dresden, Germany
Soren	Lehmann	Solna, Sweden	Adriano	Venditti	Rome, Italy
Eva	Lengfelder	Mannheim, Germany	Maria Teresa	Voso	Rome, Italy
Giuseppe	Leone	Rome, Italy	Kankan	Wang	Shanghai, China

2.00 pm Registration

3.00 - 4.00 pm **SYMPOSIUM I. Advances in diagnosis, classification and monitoring of AML**

Chair: **F. Pane**

- New developments in molecular diagnosis of AML
- The new WHO classification of AML
- MRD in AML: current status and future perspectives

*C. Thiede
B. Falini
A. Venditti*

4.00 - 5.00 pm **SYMPOSIUM II. Advances in targeted therapy of AML**

Chair: **F. Ferrara**

- FLT3 inhibitors
- Other molecular targets
- Antibody-driven therapy

*J. Sierra
R.A. Larson
S. Amadori*

5.00 - 6.00 pm **SYMPOSIUM III. Advances in diagnosis and treatment of myelodysplastic syndromes**

Chair: **E. Estey**

- Somatic mutations in diagnosis and prognosis of MDS
- Treatment of low-risk MDS
- Treatment of high-risk MDS and AML

*M.T. Voso
U. Platzbecker
P. Fenaux*

6.00 - 6.20 pm **Opening ceremony**

6.20 - 7.10 pm **KEYNOTE LECTURE**

Translational Research on the Curative Therapy for Acute Promyelocytic Leukemia

Z. Chen

7.30 - 8.30 pm *Welcome cocktail*

8.30 - 9.30 am **EDUCATIONAL SESSION. Biology, Diagnosis and Management of APL**

Chairs: **M. Alcalay, M.A. Sanz**

- Pathogenesis, diagnosis and monitoring
- Front-line therapy
- Therapy of relapse

L. Cicconi
P. Montesinos
L. Adès

9.30 - 10.30 am **PLENARY SESSION I. Molecular bases of targeted therapy and resistance**

Chairs: **F. Grignani, T. Ley**

- Mechanisms of response and resistance to epigenetic therapies
- Regulation of self renewal in cancer stem cells
- Novel insights into the basis for APL pathogenesis and therapy resistance

W.H. Miller
P.G. Pelicci

H. de Thé

10.30 - 11.00 am *Coffee break*

11.00 - 12.00 pm **PLENARY SESSION II. Genome and epigenome of APL**

Chairs: **L. Degos, P.G. Pelicci**

- Genomic and transcriptomic landscapes of acute promyelocytic leukemia
- The APL epigenome
- SELECTED ABSTRACT

K. Wang
T. Ley

12.00 - 1.00 pm **SIMULTANEOUS ORAL SESSION I
Oncogenic signalling and drug resistance**

Chairs: **S. Minucci, C. Nervi**

- SELECTED ABSTRACTS

12.00 - 1.00 pm **SIMULTANEOUS ORAL SESSION II
Clinical studies**

Chairs: **S. Lehmann, M. Tallman**

- SELECTED ABSTRACTS

1.00 - 2.20 pm *Lunch*

2.20 - 3.20 pm

PLENARY SESSION III. Early Death and Population-based studies

Chairs: **B. Lowenberg, E. Rego**

- Observational studies in APL: what have we learned and what can we still learn?
- Early deaths as the most significant threat to APL patients in real life
- Reproducing clinical trial results in the "REAL WORLD". The Georgia and South Carolina (USA) APL experience
- SELECTED ABSTRACT

M. Seftel

S. Lehmann

A. Jillella

3.20 - 4.20 pm

PLENARY SESSION IV. Management of APL in developing countries

Chairs: **N. Berliner, P. Fenaux**

- Long term follow up of the International Consortium on Acute Promyelocytic Leukemia: achievements and limitations
- Progress and Constraints in treating APL in India
- SELECTED ABSTRACT

E. Rego

M. Chandy

4.40 - 6.10 pm

TOMY'S AWARD FOR YOUNG INVESTIGATORS

9.00 - 10.00 am

SIMULTANEOUS ORAL SESSION III. Molecular Biology and Diagnostics

Chairs: **V. Mathews, C. Thiede**

- SELECTED ABSTRACTS

9.00 - 10.00 am

SIMULTANEOUS ORAL SESSION IV. Prognostic factors and Treatment

Chairs: **H. Iland, N. Russell**

- SELECTED ABSTRACTS

10.00 - 11.40 am

PLENARY SESSION V. Update in Frontline trials (I)

Chair: **M. Seftel**

- Update of the Italian-German study APL0406
- Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytic Leukemia with Different Risk Stratifications: a Interim Analysis of China APL 2012 Study
- Recent results from the prospective studies on APL in the Japan Adult Leukemia Study Group (JALSG)
- An update of APL 2006 trial results
- Update on PETHEMA trials

G. Avvisati

J. Li

A. Takeshita

P. Fenaux

M.A. Sanz

11.40 - 12.00 pm *Coffee break*

12.00 - 1.20 pm

PLENARY SESSION VI. Update in Frontline trials (Cont'd)

Chair: **M. Seftel**

- The ALLG approach to incorporating arsenic trioxide: APML4 (final analysis) and APML5 (encapsulating therapy)
- Potential for non conventional agents in upfront and relapsed APL
- Long term follow up of the NCRI AML17 Trial of attenuated Arsenic Trioxide and ATRA therapy for newly diagnosed and relapsed Acute Promyelocytic Leukaemia
- Implications for AML Clinical Trials From Experience with ATO + ATRA

H. Iland

V. Mathews

N. Russell

E. Estey

1.20 - 2.30 pm

Lunch

2.30 - 3.20 pm

PLENARY SESSION VII. The APL coagulopathy

Chairs: **G. Avvisati, M. Chandy**

- APL fatal bleeding and thrombosis in the ATRA era
- Thrombohemorrhagic disorders in APL: the unsolved issue
- SELECTED ABSTRACT

A. Falanga

P. Montesinos

3.20 - 4.20 pm

PLENARY SESSION VIII. APL in Children and the Elderly

Chairs: **R.A. Larson, F. Locatelli**

- Obesity and Initial High White Blood Cell Count are Predictors of Thrombo-hemorrhagic Early Deaths in Children and Adolescents with t(15;17) positive Acute Promyelocytic Leukemia
- Risk-adapted ATRA and chemotherapy in children with newly diagnosed Acute Promyelocytic Leukemia: a 15-year multicentric experience
- Characteristics and outcome of elderly APL patients treated with PETHEMA protocols

O. Abl

A. Testi

D. Martínez-Cuadrón

4.20 - 6.00 pm

POSTER VIEWING

8.30 - 9.30 am

PLENARY SESSION IX. Management of relapse and role of stem cell transplantation

Chair: **W. Arcese**

- Which is the best treatment for relapsed APL?
- Arsenic trioxide for the management of relapsed APL patients
- Role of transplantation in APL

E. Lengfelder

M. Breccia

J. Sanz Caballer

9.30 - 10.30 am

PLENARY SESSION X. APL as a second tumor and t-MN after APL

Chairs: **G. Leone, P. Montesinos**

- Is APL occurring as a second malignancy different from de novo APL?
- Mitoxantrone related t-APL

R.A. Larson

S.K. Hasan

10.30 - 11.00 am *Coffee break*

11.00 - 12.00 pm

PLENARY SESSION XI. Quality of life and Health Economics

Chair: **M. Breccia**

- Short and Long-Term Quality of Life Outcomes in Patients with Acute Promyelocytic Leukemia
- SELECTED ABSTRACT

F. Efficace

12.00 pm

Closing remarks

F. Lo Coco

M.A. Sanz

SCIENTIFIC SECRETARIAT

Massimo Breccia
Claudia Carissimo
Laura Cicconi
Serena Lavorgna
Maria Teresa Voso
E-mail: segr.apl2017@gmail.com

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Tel. +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

www.apl2017.com